ShapeAce (603168.SH) obtained the “Drug Supplement Application Approval Notice” for levofloxacin eye drops

Zhitongcaijing · 05/09 07:49

Zhitong Finance App News, ShapeAce (603168.SH) issued an announcement. Recently, the company received the “Drug Supplement Application Approval Notice” (Notice Number: 2025B01972) for levofloxacin eye drops issued by the State Drug Administration. After review, the application for this product complied with the relevant requirements for drug registration and approved the supplementary application for research and control strategies for nitrosamine impurities in this product.

The company has now obtained the “Drug Supplement Application Approval Notice” for levofloxacin eye drops, improving the safety information on the drug, contributing to the safe, effective and rational use of the drug, and improving the market competitiveness of this product.